Nuvo Research announced that the FDA has granted final approval on its Abbreviated New Drug Application (ADNA) for Diclofenac Sodium Topical Solution 1.5%, the generic version of Mallinckrodt’s Pennsaid 1.5% w/w. Pennsaid is a topical nonsteroidal anti-inflammatory drug (NSAID) indicated for osteoarthritis pain of the knee.
RELATED: Pennsaid 2% Solution Now Available
Diclofenac inhibits the enzyme cyclooxygenase (COX), an early component of the arachidonic acid cascade, resulting in the reduced formation of prostaglandins, thromboxanes and prostacylin.
For more information visit NuvoResearch.com.